NO325020B1 - Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett - Google Patents

Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett Download PDF

Info

Publication number: NO325020B1
Authority: NO; Norway
Prior art keywords: bnp; antibody; mammalian; derivatives; immunoassay
Prior art date: 1997-09-11

Application number

NO20001273A

Other languages

English (en)

Norwegian (no)

Other versions

NO20001273L (no

NO20001273D0 (no

Inventor

Hidehisa Asada

Hiroyuki Shimizu

Kazuaki Endou

Original Assignee

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-11

Filing date

2000-03-10

Publication date

2008-01-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17152093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO325020(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-10 Application filed by Shionogi & Co filed Critical Shionogi & Co

2000-03-10 Publication of NO20001273D0 publication Critical patent/NO20001273D0/no

2000-05-10 Publication of NO20001273L publication Critical patent/NO20001273L/no

2008-01-14 Publication of NO325020B1 publication Critical patent/NO325020B1/no

Links

238000004458 analytical method Methods 0.000 title description 23
238000003018 immunoassay Methods 0.000 claims abstract description 23
108010080850 prepro-brain natriuretic peptide Proteins 0.000 claims abstract description 10
150000001413 amino acids Chemical class 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 13
125000003275 alpha amino acid group Chemical group 0.000 claims description 11
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
239000003550 marker Substances 0.000 claims description 3
239000002245 particle Substances 0.000 claims description 3
230000002285 radioactive effect Effects 0.000 claims description 3
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 57
102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 57
101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 55
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 55
238000000034 method Methods 0.000 description 19
210000004369 blood Anatomy 0.000 description 18
239000008280 blood Substances 0.000 description 18
238000005259 measurement Methods 0.000 description 16
239000000243 solution Substances 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 13
101800001288 Atrial natriuretic factor Proteins 0.000 description 12
101800001890 Atrial natriuretic peptide Proteins 0.000 description 12
102400001282 Atrial natriuretic peptide Human genes 0.000 description 12
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 12
108090000765 processed proteins & peptides Proteins 0.000 description 12
208000019622 heart disease Diseases 0.000 description 11
206010019280 Heart failures Diseases 0.000 description 10
238000003745 diagnosis Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
238000002523 gelfiltration Methods 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 5
239000004793 Polystyrene Substances 0.000 description 5
239000004365 Protease Substances 0.000 description 5
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
239000005556 hormone Substances 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
229920002223 polystyrene Polymers 0.000 description 5
230000028327 secretion Effects 0.000 description 5
238000005406 washing Methods 0.000 description 5
108010039627 Aprotinin Proteins 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 4
239000012505 Superdex™ Substances 0.000 description 4
229960004405 aprotinin Drugs 0.000 description 4
238000003149 assay kit Methods 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000010828 elution Methods 0.000 description 4
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000001452 natriuretic effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108020001621 Natriuretic Peptide Proteins 0.000 description 3
102000004571 Natriuretic peptide Human genes 0.000 description 3
239000011324 bead Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000000692 natriuretic peptide Substances 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000000047 product Substances 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000012491 analyte Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000013076 target substance Substances 0.000 description 2
229960001479 tosylchloramide sodium Drugs 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
101500026746 Canis lupus familiaris Brain natriuretic peptide 32 Proteins 0.000 description 1
102000004961 Furin Human genes 0.000 description 1
108090001126 Furin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
101710118538 Protease Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000002837 heart atrium Anatomy 0.000 description 1
230000004217 heart function Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pathology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)

NO20001273A 1997-09-11 2000-03-10 Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett NO325020B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP24668497		1997-09-11
PCT/JP1998/004063 WO1999013331A1 (fr)	1997-09-11	1998-09-10	Procede de dosage immunologique pour bnp

Publications (3)

Publication Number	Publication Date
NO20001273D0 NO20001273D0 (no)	2000-03-10
NO20001273L NO20001273L (no)	2000-05-10
NO325020B1 true NO325020B1 (no)	2008-01-14

Family

ID=17152093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20001273A NO325020B1 (no)	1997-09-11	2000-03-10	Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett

Country Status (13)

Country	Link
US (1)	US6828107B2 (fr)
EP (1)	EP1016867B1 (fr)
JP (1)	JP3516655B2 (fr)
KR (1)	KR100563358B1 (fr)
CN (1)	CN1161609C (fr)
AT (1)	ATE315228T1 (fr)
AU (1)	AU731858B2 (fr)
CA (1)	CA2304263C (fr)
DE (1)	DE69833118T2 (fr)
DK (1)	DK1016867T3 (fr)
ES (1)	ES2256952T3 (fr)
NO (1)	NO325020B1 (fr)
WO (1)	WO1999013331A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030199000A1 (en) *	2001-08-20	2003-10-23	Valkirs Gunars E.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7524635B2 (en) *	2003-04-17	2009-04-28	Biosite Incorporated	Methods and compositions for measuring natriuretic peptides and uses thereof
US7632647B2 (en) *	2001-04-13	2009-12-15	Biosite Incorporated	Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030219734A1 (en) *	2001-04-13	2003-11-27	Biosite Incorporated	Polypeptides related to natriuretic peptides and methods of their identification and use
US20040176914A1 (en) *	2001-04-13	2004-09-09	Biosite Incorporated	Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US7608406B2 (en) *	2001-08-20	2009-10-27	Biosite, Inc.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040219509A1 (en) *	2001-08-20	2004-11-04	Biosite, Inc.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) *	2001-08-20	2004-10-21	Biosite Incorporated	Diagnostic markers of stroke and cerebral injury and methods of use thereof
JP2005522669A (ja) *	2001-08-20	2005-07-28	バイオサイトインコーポレイテッド	卒中および脳損傷の診断マーカーおよびその使用方法
JP3691803B2 (ja) *	2002-03-14	2005-09-07	三洋化成工業株式会社	血液中の心不全マーカー定量方法
AUPS169202A0 (en) *	2002-04-11	2002-05-16	Goetze, Jens Peter	Neuropeptide assay
DK3072978T3 (en)	2002-05-09	2018-09-17	Brigham & Womens Hospital Inc	: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
FR2843396B1 (fr) *	2002-08-07	2005-04-15	Bio Rad Pasteur	Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
US7135329B2 (en) *	2002-11-18	2006-11-14	Princeton Biomeditech Corporation	Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
US7109023B2 (en) *	2002-11-18	2006-09-19	Princeton Biomeditech Corporation	Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
EP1625164B1 (fr) *	2003-05-12	2011-07-20	Roche Diagnostics GmbH	Methode de detection du probnp a l'aide d'un anticorps monoclonal liant les acides amines 42 à 46
PT1638443E (pt) *	2003-06-20	2011-01-25	Mayo Foundation	Isoformas de péptido natriurético cerebral
US20080182299A1 (en) *	2004-01-27	2008-07-31	Compugent Ltd.	Novel brain natriuretic peptide variants and methods of use thereof
JP2007525213A (ja) *	2004-01-27	2007-09-06	コンピュゲンユーエスエイ，インク．	新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法
EP2264463A3 (fr) *	2004-03-19	2011-08-10	Biomedica Medizinprodukte GmbH & Co KG	Techniques de pronostic d'insuffisance cardiaque congestive
AT500800B1 (de)	2004-09-08	2008-07-15	Biomedica Medizinprodukte Gmbh	Verfahren zur bestimmung von probnp
WO2006031583A2 (fr) *	2004-09-09	2006-03-23	Biosite Incorporated	Compositions et methodes de mesure des peptides bnp de canines et leurs utilisations
US7731965B2 (en) *	2005-02-17	2010-06-08	Abbott Lab	Human ring specific BNP antibodies
CA2629438C (fr)	2005-11-09	2014-02-25	Abbott Laboratories	Anticorps immunospecifiques du bnp humain
US7939069B2 (en)	2005-11-09	2011-05-10	Abbott Laboratories	Human BNP immunospecific antibodies
AU2007244927B2 (en)	2006-04-24	2012-01-12	Critical Care Diagnostics, Inc.	Predicting mortality and detecting severe disease
EP2021796B1 (fr)	2006-05-01	2012-02-08	Critical Care Diagnostics, Inc.	Procédé de diagnostic d'une maladie cardiovasculaire
CA2660294C (fr) *	2006-08-08	2017-08-29	Mayo Foundation For Medical Education And Research	Polypeptides diuretiques et natriuretiques
US20080064045A1 (en)	2006-09-07	2008-03-13	Huaiqin Wu	Biomarker fragments for the detection of human BNP
US20080108147A1 (en) *	2006-11-03	2008-05-08	Tie Wei	Reduction of non-specific binding in immunoassays
WO2008095052A2 (fr)	2007-01-30	2008-08-07	Loma Vista Medical, Inc.,	Dispositif de navigation biologique
AT504942B1 (de)	2007-03-07	2009-08-15	Biomedica Medizinprodukte Gmbh	Verfahren zur bestimmung von probnp
FI20075251A0 (fi)	2007-04-13	2007-04-13	Hytest Oy	Immunomääritys epästabiilien antigeenien määrittämiseksi
JP5570415B2 (ja) *	2007-05-08	2014-08-13	アボット・ラボラトリーズ	他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
US8357656B2 (en) *	2007-09-15	2013-01-22	Mayo Foundation For Medical Education And Research	Natriuretic peptide receptor-C agonists
WO2009086126A2 (fr) *	2007-12-21	2009-07-09	Mayo Foundation For Medical Education And Research	Polypeptides natriurétiques
PL2269063T3 (pl)	2008-04-18	2014-04-30	Critical Care Diagnostics Inc	Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych
WO2009149108A1 (fr)	2008-06-02	2009-12-10	Loma Vista Medical, Inc.	Dispositifs médicaux gonflables
WO2010077654A1 (fr) *	2008-12-08	2010-07-08	Biosite Incorporated	Dosages de peptides natriurétiques combinés
CN101923090A (zh) *	2009-06-10	2010-12-22	中国科学院电子学研究所	固定人体脑钠肽的光学敏感膜的制备方法
US9592119B2 (en)	2010-07-13	2017-03-14	C.R. Bard, Inc.	Inflatable medical devices
US8778699B2 (en)	2010-08-04	2014-07-15	Idexx Laboratories, Inc.	Detection of degradation products of canine NT-proBNP
US10188436B2 (en)	2010-11-09	2019-01-29	Loma Vista Medical, Inc.	Inflatable medical devices
AU2012262154B2 (en)	2011-05-31	2016-08-04	Idexx Laboratories, Inc.	Detection of degradation products of feline NT-proBNP
CN107090028A (zh)	2011-08-30	2017-08-25	梅约医学教育与研究基金会	利钠多肽
US9611305B2 (en)	2012-01-06	2017-04-04	Mayo Foundation For Medical Education And Research	Treating cardiovascular or renal diseases
CN104737170A (zh)	2012-08-21	2015-06-24	重症监护诊断股份有限公司	多标记风险分层
CN112710852B (zh) *	2021-03-26	2021-08-03	上海美迪西生物医药股份有限公司	一种gnp多肽的检测试剂盒及检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2676114B2 (ja) *	1990-04-16	1997-11-12	塩野義製薬株式会社	ｈＢＮＰを認識するモノクローナル抗体および該抗体を用いるｈＢＮＰの免疫測定法
GB9211686D0 (en) *	1992-06-03	1992-07-15	Medisinsk Innovation A S	Chemical compounds

1998
- 1998-09-10 CN CNB988110539A patent/CN1161609C/zh not_active Expired - Fee Related
- 1998-09-10 WO PCT/JP1998/004063 patent/WO1999013331A1/fr not_active Ceased
- 1998-09-10 US US09/508,435 patent/US6828107B2/en not_active Expired - Lifetime
- 1998-09-10 DE DE69833118T patent/DE69833118T2/de not_active Expired - Lifetime
- 1998-09-10 KR KR1020007002530A patent/KR100563358B1/ko not_active Expired - Fee Related
- 1998-09-10 AU AU90010/98A patent/AU731858B2/en not_active Ceased
- 1998-09-10 JP JP2000511064A patent/JP3516655B2/ja not_active Expired - Fee Related
- 1998-09-10 CA CA002304263A patent/CA2304263C/fr not_active Expired - Fee Related
- 1998-09-10 ES ES98941797T patent/ES2256952T3/es not_active Expired - Lifetime
- 1998-09-10 EP EP98941797A patent/EP1016867B1/fr not_active Expired - Lifetime
- 1998-09-10 AT AT98941797T patent/ATE315228T1/de not_active IP Right Cessation
- 1998-09-10 DK DK98941797T patent/DK1016867T3/da active
2000
- 2000-03-10 NO NO20001273A patent/NO325020B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69833118T2 (de)	2006-08-31
EP1016867A4 (fr)	2004-11-17
AU9001098A (en)	1999-03-29
KR100563358B1 (ko)	2006-03-22
EP1016867B1 (fr)	2006-01-04
NO20001273L (no)	2000-05-10
KR20010023853A (ko)	2001-03-26
US6828107B2 (en)	2004-12-07
DE69833118D1 (de)	2006-03-30
ATE315228T1 (de)	2006-02-15
EP1016867A1 (fr)	2000-07-05
CA2304263C (fr)	2008-07-29
NO20001273D0 (no)	2000-03-10
CN1161609C (zh)	2004-08-11
AU731858B2 (en)	2001-04-05
US20030157596A1 (en)	2003-08-21
ES2256952T3 (es)	2006-07-16
WO1999013331A1 (fr)	1999-03-18
JP3516655B2 (ja)	2004-04-05
DK1016867T3 (da)	2006-05-22
CA2304263A1 (fr)	1999-03-18
CN1278919A (zh)	2001-01-03

Legal Events

Date	Code	Title	Description
2018-04-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO325020B1 (no)	2008-01-14	Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett
JPWO1999013331A1 (ja)	2002-08-20	Ｂｎｐの免疫測定法
Struck et al.	2005	Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients
US9151766B2 (en)	2015-10-06	Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems
JP4932714B2 (ja)	2012-05-16	コペプチンを使用する疾患の診断方法
Prontera et al.	2004	Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay...
US7534582B2 (en)	2009-05-19	Method for measuring the amount of natriuretic peptides in a sample
US7977072B2 (en)	2011-07-12	Sandwich immunoassay for identifying partial proANP peptides
JP2005510234A (ja)	2005-04-21	ポリペプチドの定量
Wijbenga et al.	1999	Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practice
JP5734547B2 (ja)	2015-06-17	生物学的液体中のナトリウム利尿ペプチドのサンプリングのための方法、組成物、および装置
JP4294961B2 (ja)	2009-07-15	試料中の実効的な副甲状腺ホルモン活性の測定方法
CN109946461A (zh)	2019-06-28	一种b型利钠肽前体化学发光检测试剂盒及其制备方法
Jüppner et al.	1986	Radioimmunoassay for human osteocalcin using an antibody raised against the synthetic human (h37–49) sequence
US7226729B1 (en)	2007-06-05	Method for inhibiting degradation of brain natriuretic peptides
Erfurt et al.	2013	Secretion of Prohormone of B-Type Natriuretic Peptide, proBNP1-108, Is Increased in Heart Failure
HK1241021A1 (en)	2018-06-01	Nt-proanp and nt-probnp for the diagnosis of stroke
HK1201327B (en)	2018-01-26	Nt-proanp and nt-probnp for the diagnosis of stroke
HK1201327A1 (en)	2015-08-28	Nt-proanp and nt-probnp for the diagnosis of stroke